JAK-IN-5 hydrochloride

CAS No. 2751323-21-2

JAK-IN-5 hydrochloride( JAK-IN-5 hydrochloride(2096999-92-5 Free base) )

Catalog No. M26264 CAS No. 2751323-21-2

JAK-IN-5 hydrochloride is an inhibitor of JAK.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 1224 Get Quote
50MG 1899 Get Quote
100MG 2835 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    JAK-IN-5 hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    JAK-IN-5 hydrochloride is an inhibitor of JAK.
  • Description
    JAK-IN-5 hydrochloride is an inhibitor of JAK.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    JAK-IN-5 hydrochloride(2096999-92-5 Free base)
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    TRPML1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2751323-21-2
  • Formula Weight
    511.03
  • Molecular Formula
    C27H32ClFN6O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [H]Cl.OC1=CC(CC)=C(C2=CC3=C(C=C2)C(C(N4)=NC5=C4CN(C6CCN(C)CC6)CC5)=NN3)C=C1F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Chen CC, Keller M et al. A small molecule restores function to TRPML1 mutant isoforms responsible for mucolipidosis type IV. Nat Commun. 2014 Aug 14;5:4681.
molnova catalog
related products
  • WP1066

    WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells.

  • ZM39923 hydrochlorid...

    ZM39923 is a potent, selective JAK3 inhibitor with pIC50 of 7.1.

  • PF-06651600

    PF-06651600 is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2; inhibits Th1 and Th17 cell differentiation and function, reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models; selectively targets γc cytokine pathways while preserving JAK1-dependent anti-inflammatory signaling such as the IL-10 suppressive functions following LPS treatment in macrophages and the suppression of TNFα and IL-1β production in IL-27-primed macrophages.Rheumatoid ArthritisPhase 2 Clinical